ALDEYRA THERAPEUTICS, INC. Retained Earnings
ALDEYRA THERAPEUTICS, INC. (ALDX) had Retained Earnings of -$492.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$492.86M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$487.41M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$483.96M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$477.50M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$492.86M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$487.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$483.96M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$477.50M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$469.81M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$460.04M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$450.11M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$434.30M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$419.19M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$402.34M 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$394.26M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$389.51M 10-Q · filed 2023-11-03 |
| 2023-06-30 | -$381.32M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$372.33M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$356.72M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$343.81M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$329.26M 10-Q · filed 2022-08-05 |
| 2022-03-31 | -$311.48M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$294.69M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$278.94M 10-Q · filed 2021-10-28 |
| 2021-06-30 | -$263.14M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$248.21M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$236.92M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$225.62M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$216.75M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$209.23M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$199.36M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$186.20M 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$167.49M 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$154.16M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$138.54M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$127.90M 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$117.09M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$108.04M 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$99.64M 10-K · filed 2019-03-08 |
| 2017-09-30 | -$92.69M 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$87.70M 10-Q · filed 2017-08-07 |
| 2017-03-31 | -$82.39M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$77.30M 10-K · filed 2018-03-29 |
| 2016-09-30 | -$72.65M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$67.87M 10-Q · filed 2016-08-10 |
| 2016-03-31 | -$63.57M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$58.60M 10-K · filed 2017-03-30 |
| 2015-09-30 | -$54.25M 10-Q · filed 2015-11-13 |
| 2015-06-30 | -$50.88M 10-Q · filed 2015-08-14 |
| 2015-03-31 | -$48.65M 10-Q · filed 2015-05-14 |
| 2014-12-31 | -$46.51M 10-K · filed 2016-03-30 |
| 2014-09-30 | -$44.07M 10-Q · filed 2014-11-12 |
| 2014-06-30 | -$42.06M 10-Q · filed 2014-08-07 |
| 2013-12-31 | -$41.32M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |